United States (US) PD-1/PD-L1 immunotherapy Market (2025-2031) Outlook | Analysis, Size, Value, Growth, Revenue, Share, Companies, Forecast, Industry & Trends

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 United States (US) Country Macro Economic Indicators

3.2 United States (US) PD-1/PD-L1 immunotherapy Market Revenues & Volume, 2021 & 2031F

3.3 United States (US) PD-1/PD-L1 immunotherapy Market - Industry Life Cycle

3.4 United States (US) PD-1/PD-L1 immunotherapy Market - Porter's Five Forces

3.5 United States (US) PD-1/PD-L1 immunotherapy Market Revenues & Volume Share, By Type, 2021 & 2031F

3.6 United States (US) PD-1/PD-L1 immunotherapy Market Revenues & Volume Share, By Form, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of cancer in the United States

4.2.2 Growing adoption of immunotherapy as a preferred treatment option

4.2.3 Technological advancements in PD-1/PD-L1 therapies

4.3 Market Restraints

4.3.1 High cost associated with PD-1/PD-L1 immunotherapy

4.3.2 Stringent regulatory requirements for drug approval

4.3.3 Potential side effects and adverse reactions of immunotherapy

6.1 United States (US) PD-1/PD-L1 immunotherapy Market, By Type

6.1.1 Overview and Analysis

6.1.2 United States (US) PD-1/PD-L1 immunotherapy Market Revenues & Volume, By Type, 2018 - 2027F

6.1.3 United States (US) PD-1/PD-L1 immunotherapy Market Revenues & Volume, By CTLA-4 Inhibitor, 2018 - 2027F

6.1.4 United States (US) PD-1/PD-L1 immunotherapy Market Revenues & Volume, By PD-1 Inhibitor, 2018 - 2027F

6.1.5 United States (US) PD-1/PD-L1 immunotherapy Market Revenues & Volume, By PDL-1 Inhibitor, 2018 - 2027F

6.1.6 United States (US) PD-1/PD-L1 immunotherapy Market Revenues & Volume, By Others, 2018 - 2027F

6.2 United States (US) PD-1/PD-L1 immunotherapy Market, By Application

6.2.1 Overview and Analysis

6.2.2 United States (US) PD-1/PD-L1 immunotherapy Market Revenues & Volume, By Melanoma, 2018 - 2027F

6.2.3 United States (US) PD-1/PD-L1 immunotherapy Market Revenues & Volume, By Lung Cancer, 2018 - 2027F

6.2.4 United States (US) PD-1/PD-L1 immunotherapy Market Revenues & Volume, By Bladder Cancer, 2018 - 2027F

6.2.5 United States (US) PD-1/PD-L1 immunotherapy Market Revenues & Volume, By Others, 2018 - 2027F

7.1 United States (US) PD-1/PD-L1 immunotherapy Market Export to Major Countries

7.2 United States (US) PD-1/PD-L1 immunotherapy Market Imports from Major Countries

8.1 Patient response rate to PD-1/PD-L1 immunotherapy

8.2 Number of ongoing clinical trials for new PD-1/PD-L1 drugs

8.3 Adoption rate of PD-1/PD-L1 immunotherapy by healthcare providers

8.4 Average length of time for FDA approval of new PD-1/PD-L1 therapies

8.5 Investment in research and development for improving PD-1/PD-L1 treatments

9.1 United States (US) PD-1/PD-L1 immunotherapy Market Opportunity Assessment, By Type, 2021 & 2031F

9.2 United States (US) PD-1/PD-L1 immunotherapy Market Opportunity Assessment, By Application, 2021 & 2031F

10.1 United States (US) PD-1/PD-L1 immunotherapy Market Revenue Share, By Companies, 2021

10.2 United States (US) PD-1/PD-L1 immunotherapy Market Competitive Benchmarking, By Operating and Technical Parameters